A Clinical Study on the Safety and Efficacy of GCC Targeting CAR-T Cells (WD-01) for Metastatic Colorectal Cancer
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs REVO UWD 01 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Wondercel Therapeutics
- 18 Nov 2024 Status changed from not yet recruiting to recruiting.
- 08 Nov 2024 New trial record